Prolyl Endopeptidase FAP clinical trials
8 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Actinium Therapy for Late-stage Aggressive Sarcomas
- A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Imaging of Solid Tumors Using FAP-2286
- Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “Prolyl Endopeptidase FAP” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.